These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 34210955)
1. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y Blood Cancer J; 2021 Jul; 11(7):124. PubMed ID: 34210955 [No Abstract] [Full Text] [Related]
2. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Braksick SA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y Am J Hematol; 2021 Nov; 96(11):E427-E430. PubMed ID: 34424554 [No Abstract] [Full Text] [Related]
3. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319 [TBL] [Abstract][Full Text] [Related]
4. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502 [TBL] [Abstract][Full Text] [Related]
5. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Reagan PM; Friedberg JW Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873 [TBL] [Abstract][Full Text] [Related]
6. Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. Grana A; Gut N; Williams K; Maakaron J; Porter K; William BM; Vasu S; Penza S; Brammer JE; Saad A; Puto M; Jaglowski SM; Roddy J Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):238-245. PubMed ID: 33132101 [TBL] [Abstract][Full Text] [Related]
7. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Oluwole OO; Bouabdallah K; Muñoz J; De Guibert S; Vose JM; Bartlett NL; Lin Y; Deol A; McSweeney PA; Goy AH; Kersten MJ; Jacobson CA; Farooq U; Minnema MC; Thieblemont C; Timmerman JM; Stiff P; Avivi I; Tzachanis D; Kim JJ; Bashir Z; McLeroy J; Zheng Y; Rossi JM; Johnson L; Goyal L; van Meerten T Br J Haematol; 2021 Aug; 194(4):690-700. PubMed ID: 34296427 [TBL] [Abstract][Full Text] [Related]
8. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR; N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224 [TBL] [Abstract][Full Text] [Related]
9. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502 [TBL] [Abstract][Full Text] [Related]
10. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801 [No Abstract] [Full Text] [Related]
13. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. Cohen JA; Ghobadi A Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133 [TBL] [Abstract][Full Text] [Related]
14. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. Melody M; Gandhi S; Rahman ZA; Lengerke-Diaz P; Gannon N; Rosenthal A; Truong T; Novo M; Brandes E; Lange G; Estby B; Johnston P; Ansell S; Bennani NN; Paludo J; Bisneto JV; Ayala E; Tun HW; Murthy HS; Roy V; Foran J; Castro J; Lin Y; Kharfan-Dabaja MA Eur J Haematol; 2021 Jul; 107(1):48-53. PubMed ID: 33655560 [TBL] [Abstract][Full Text] [Related]
15. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. Locke FL; Go WY; Neelapu SS JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310 [TBL] [Abstract][Full Text] [Related]
16. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Hamilton MP; Sugio T; Noordenbos T; Shi S; Bulterys PL; Liu CL; Kang X; Olsen MN; Good Z; Dahiya S; Frank MJ; Sahaf B; Mackall CL; Gratzinger D; Diehn M; Alizadeh AA; Miklos DB N Engl J Med; 2024 Jun; 390(22):2047-2060. PubMed ID: 38865660 [TBL] [Abstract][Full Text] [Related]